The story of copyright's flagship drug presents a interesting case for investors in the pharmaceutical sector. While initially a phenomenal success, producing huge profits, the exclusivity expiration and the subsequent flood of cheaper versions have considerably changed earnings. This presents questions about the future profitability of analogou… Read More